About this trial
The Norwegian Spontaneous Coronary Artery Dissection Study (NOR-SCAD) is a national, multicenter prospective observational study conducted at major hospitals in Norway. The study investigates risk factors and complications of spontaneous coronary artery dissection (SCAD). Patients aged 18 years or older who are hospitalized with SCAD are recruited during the index hospitalization. Each participant will be followed for 52 weeks with scheduled visits at 8 and 12 weeks and a final phone call at 52 weeks. Evaluations include coronary CT angiography (CTA), cardiac assessments, genetic analyses, blood sampling, structured questionnaires, and a cardiopulmonary exercise test (CPET).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Spontaneous coronary artery dissection
Disqualifiers
Severe kidney failure
Severe allergic reaction to contrast
Trial population
Spontaneous coronary artery dissection
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Major Adverse Cardiac Events
Recurrent myocardial infarction, extra coronary dissection, stroke/TIA, heart failure,
Secondary outcomes
Assessment of Quality of life
Quality of life assessed by questionnaire WHO-BREF
CTA
Computed tomography angiography (CTA) findings
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Oslo University Hospital
Lead sponsor
University Hospital, Akershus
Collaborator
Haukeland University Hospital, Bergen, Norway
Collaborator
Sorlandet Hospital HF
Collaborator
Universitetssykehuset i Nord-Norge HF
Collaborator
Ullevaal University Hospital
Collaborator
Helse Stavanger HF
Collaborator
St. Olavs Hospital
Collaborator